• Genmab reported three positive Phase 3 trials, supporting potential approvals and launches beginning in 2027.
• EPKINLY reduced the risk of progression or death by 51% versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.
• Rina-S cut progression or death risk by 71% versus chemotherapy in platinum-resistant ovarian cancer; overall survival also improved significantly.
• Petosemtamab with pembrolizumab reduced death risk by 50% versus pembrolizumab alone in first-line recurrent or metastatic PD-L1-positive head and neck cancer.
• Estimated peak sales opportunities exceed $3 billion for EPKINLY, exceed $2 billion for Rina-S, and reach multiple billions for petosemtamab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.